Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.

G Martin, Thomas; Victoria Mateos, Maria; Nooka, Ajay; Banerjee, Arnob; Kobos, Rachel; Pei, Lixia; Qi, Ming; Verona, Raluca; Doyle, Margaret; Smit, Jennifer; Sun, Weili; Trancucci, Danielle; Uhlar, Clarissa; W C J van de Donk, Niels; Rodriguez, Cesar

doi:10.1002/cncr.34756

Public

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.

Shared by NobleBlocks on Jul 1, 2023 • 12:00 AM UTC

Authors:

Thomas G Martin

Maria Victoria Mateos

Ajay Nooka

Abstract

BACKGROUND: Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, demonstrated an overall response rate of 63.0% in 165 heavily pretreated patients with relapsed or refractory multiple myeloma in the phase 1/2 MajesTEC-1 study. Cytokine release syndrome (CRS), a known manifestation of ...

Subject

B-cell maturation antigen

antibodies

bispecific

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!